NO311965B1 - Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat - Google Patents

Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat Download PDF

Info

Publication number: NO311965B1
Authority: NO; Norway
Prior art keywords: use according; antibody; vcd44; cells; diseases
Prior art date: 1991-10-23

Application number

NO19924103A

Other languages

English (en)

Norwegian (no)

Other versions

NO924103D0 (no

NO924103L (no

Inventor

Margot Zoeller

Peter Herrlich

Helmut Ponta

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-23

Filing date

1992-10-22

Publication date

2002-02-25

1992-10-22 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

1992-10-22 Publication of NO924103D0 publication Critical patent/NO924103D0/no

1993-04-26 Publication of NO924103L publication Critical patent/NO924103L/no

2002-02-25 Publication of NO311965B1 publication Critical patent/NO311965B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 20
239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
108010052285 Membrane Proteins Proteins 0.000 title claims description 6
102000018697 Membrane Proteins Human genes 0.000 title claims description 5
241000282414 Homo sapiens Species 0.000 claims description 24
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
102100032912 CD44 antigen Human genes 0.000 claims description 17
210000001744 T-lymphocyte Anatomy 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 12
239000012634 fragment Substances 0.000 claims description 12
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
230000004913 activation Effects 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 7
210000004408 hybridoma Anatomy 0.000 claims description 7
210000000987 immune system Anatomy 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 5
239000007924 injection Substances 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
210000003719 b-lymphocyte Anatomy 0.000 claims description 4
230000008629 immune suppression Effects 0.000 claims description 4
230000004957 immunoregulator effect Effects 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
230000001629 suppression Effects 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
208000023275 Autoimmune disease Diseases 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 3
230000003463 hyperproliferative effect Effects 0.000 claims description 3
230000002757 inflammatory effect Effects 0.000 claims description 3
238000001802 infusion Methods 0.000 claims description 3
230000002062 proliferating effect Effects 0.000 claims description 3
206010012438 Dermatitis atopic Diseases 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
230000005867 T cell response Effects 0.000 claims description 2
201000008937 atopic dermatitis Diseases 0.000 claims description 2
230000003412 degenerative effect Effects 0.000 claims description 2
208000026278 immune system disease Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000010412 perfusion Effects 0.000 claims description 2
230000000552 rheumatic effect Effects 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 2
238000011200 topical administration Methods 0.000 claims 1
230000001506 immunosuppresive effect Effects 0.000 abstract description 7
206010062016 Immunosuppression Diseases 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 69
241000700159 Rattus Species 0.000 description 47
150000001413 amino acids Chemical group 0.000 description 24
238000000034 method Methods 0.000 description 24
108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
108020004414 DNA Proteins 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 14
210000004881 tumor cell Anatomy 0.000 description 14
230000003053 immunization Effects 0.000 description 13
238000002649 immunization Methods 0.000 description 13
210000004698 lymphocyte Anatomy 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
239000000427 antigen Substances 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
206010061289 metastatic neoplasm Diseases 0.000 description 10
238000003752 polymerase chain reaction Methods 0.000 description 10
241000282412 Homo Species 0.000 description 9
206010027476 Metastases Diseases 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
108090000288 Glycoproteins Proteins 0.000 description 8
102000003886 Glycoproteins Human genes 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
239000000523 sample Substances 0.000 description 8
230000009401 metastasis Effects 0.000 description 7
230000001394 metastastic effect Effects 0.000 description 7
210000004989 spleen cell Anatomy 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
210000005260 human cell Anatomy 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
238000012270 DNA recombination Methods 0.000 description 5
230000000735 allogeneic effect Effects 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000000683 nonmetastatic effect Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 4
108700024394 Exon Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
108091034057 RNA (poly(A)) Proteins 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000007124 immune defense Effects 0.000 description 4
201000009546 lung large cell carcinoma Diseases 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
239000000047 product Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920006926 PFC Polymers 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
102100038567 Properdin Human genes 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
230000007815 allergy Effects 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013598 vector Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000699662 Cricetomys gambianus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108010092694 L-Selectin Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
108010087066 N2-tryptophyllysine Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000018359 Systemic autoimmune disease Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000409 cytocidal Toxicity 0.000 description 1
230000000445 cytocidal effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
102000048851 human CD44 Human genes 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002625 monoclonal antibody therapy Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
210000001986 peyer's patch Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000004289 sodium hydrogen sulphite Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO19924103A 1991-10-23 1992-10-22 Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat NO311965B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4134982A DE4134982A1 (de)	1991-10-23	1991-10-23	Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Publications (3)

Publication Number	Publication Date
NO924103D0 NO924103D0 (no)	1992-10-22
NO924103L NO924103L (no)	1993-04-26
NO311965B1 true NO311965B1 (no)	2002-02-25

Family

ID=6443260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19924103A NO311965B1 (no)	1991-10-23	1992-10-22	Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat

Country Status (17)

Country	Link
US (1)	US5951982A (fr)
EP (1)	EP0538754B1 (fr)
JP (1)	JPH05310596A (fr)
KR (1)	KR100252620B1 (fr)
AT (1)	ATE162079T1 (fr)
AU (1)	AU659687B2 (fr)
CA (1)	CA2081150C (fr)
DE (2)	DE4134982A1 (fr)
DK (1)	DK0538754T3 (fr)
ES (1)	ES2111031T3 (fr)
GR (1)	GR3026526T3 (fr)
HU (1)	HU216020B (fr)
IL (1)	IL103510A0 (fr)
NO (1)	NO311965B1 (fr)
NZ (1)	NZ244851A (fr)
TW (1)	TW273514B (fr)
ZA (1)	ZA928162B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5589458A (en) *	1992-11-13	1996-12-31	Thomas Jefferson University	Compounds that inhibit T cell proliferation and methods for using the same
ES2110764T3 (es) *	1993-06-18	1998-02-16	Biotie Therapies Oy	Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.
DE4326573A1 (de) *	1993-08-07	1995-02-23	Boehringer Ingelheim Int	Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) *	1994-09-02	1996-03-07	Boehringer Ingelheim Int	Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) *	1995-10-31	1997-02-06	Boehringer Ingelheim Int	Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
AU1672097A (en) *	1996-02-15	1997-09-02	Chugai Seiyaku Kabushiki Kaisha	Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
US6136311A (en)	1996-05-06	2000-10-24	Cornell Research Foundation, Inc.	Treatment and diagnosis of cancer
DE19652815C2 (de) *	1996-12-18	1999-11-11	Karlsruhe Forschzent	Mittel zur Identifizierung und Therapie metastasierender Tumore
DE19653607A1 (de)	1996-12-20	1998-06-25	Boehringer Ingelheim Int	Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) *	1997-03-04	2002-11-28	Boehringer Ingelheim Int	Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
IL121656A0 (en) *	1997-08-29	1998-02-08	Yissum Res Dev Co	Diagnosis prevention and treatment of diabetes
US7534605B2 (en) *	1999-06-08	2009-05-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2004024750A2 (fr) *	2002-09-13	2004-03-25	Dyax Corporation	Ligands liant cd44
US9701754B1 (en)	2002-10-23	2017-07-11	City Of Hope	Covalent disulfide-linked diabodies and uses thereof
WO2005087264A1 (fr) *	2004-03-17	2005-09-22	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Ciblage de cd44 destine a reduire/prevenir des lesions par ischemie-reperfusion
EP2267030A1 (fr)	2005-08-25	2010-12-29	Repair Technologies, Inc.	Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US8940871B2 (en)	2006-03-20	2015-01-27	The Regents Of The University Of California	Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US8940298B2 (en)	2007-09-04	2015-01-27	The Regents Of The University Of California	High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2010058396A1 (fr)	2008-11-19	2010-05-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Anticorps anti-cd44vra et procédés diagnostiques et thérapeutiques l'utilisant
EP3495000A1 (fr)	2009-02-17	2019-06-12	Cornell Research Foundation, Inc.	Procédés et kits pour le diagnostic du cancer et la prédiction d'une valeur thérapeutique
CA3040276A1 (fr)	2009-12-02	2011-06-09	Imaginab, Inc.	Minobodies j591 et cys-diabodies pour le ciblage de l'antigene membranaire specifique de la prostate humaine (psma), et procedes d'utilisation
DK2886126T3 (en)	2013-12-23	2017-09-18	Exchange Imaging Tech Gmbh	Nanoparticle conjugated to CD44-binding peptides
BR112017000710B1 (pt)	2014-07-15	2024-02-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Polipeptídeo isolado, composição de matéria, e, uso do polipeptídeo isolado ou da composição da matéria
SG10201913625XA (en)	2015-08-07	2020-03-30	Imaginab Inc	Antigen binding constructs to target molecules
WO2018147960A1 (fr)	2017-02-08	2018-08-16	Imaginab, Inc.	Séquences d'extension pour dianticorps
US11313243B2 (en)	2018-07-12	2022-04-26	Rolls-Royce North American Technologies, Inc.	Non-continuous abradable coatings

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE114478T1 (de) *	1987-08-11	1994-12-15	Univ Leland Stanford Junior	Verfahren zur kontrolle der leukozyten- extravasation.
DE4014510A1 (de) *	1990-05-07	1991-11-14	Kernforschungsz Karlsruhe	Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
CA2059824A1 (fr) *	1991-02-26	1992-08-27	Thomas M. Aune	Hybridomes et anticorps monoclonaux qui inhibent la proliferation des lymphocytes t stimules anti-cd3
ES2110764T3 (es) *	1993-06-18	1998-02-16	Biotie Therapies Oy	Composiciones y metodos de diagnostico empleando anticuerpos monoclonales contra la cd44v6.

1991
- 1991-10-23 DE DE4134982A patent/DE4134982A1/de not_active Withdrawn
1992
- 1992-10-07 TW TW081107971A patent/TW273514B/zh active
- 1992-10-17 EP EP92117775A patent/EP0538754B1/fr not_active Expired - Lifetime
- 1992-10-17 AT AT92117775T patent/ATE162079T1/de not_active IP Right Cessation
- 1992-10-17 DE DE59209129T patent/DE59209129D1/de not_active Expired - Fee Related
- 1992-10-17 DK DK92117775.4T patent/DK0538754T3/da active
- 1992-10-17 ES ES92117775T patent/ES2111031T3/es not_active Expired - Lifetime
- 1992-10-21 NZ NZ244851A patent/NZ244851A/en unknown
- 1992-10-22 CA CA002081150A patent/CA2081150C/fr not_active Expired - Fee Related
- 1992-10-22 ZA ZA928162A patent/ZA928162B/xx unknown
- 1992-10-22 KR KR1019920019468A patent/KR100252620B1/ko not_active IP Right Cessation
- 1992-10-22 HU HUP9203337A patent/HU216020B/hu not_active IP Right Cessation
- 1992-10-22 AU AU27244/92A patent/AU659687B2/en not_active Ceased
- 1992-10-22 NO NO19924103A patent/NO311965B1/no not_active IP Right Cessation
- 1992-10-22 IL IL103510A patent/IL103510A0/xx unknown
- 1992-10-23 JP JP4307913A patent/JPH05310596A/ja active Pending
1994
- 1994-12-20 US US08/359,850 patent/US5951982A/en not_active Expired - Lifetime
1998
- 1998-04-03 GR GR980400710T patent/GR3026526T3/el unknown

Also Published As

Publication number	Publication date
EP0538754A3 (en)	1994-05-25
DK0538754T3 (da)	1998-03-30
JPH05310596A (ja)	1993-11-22
AU659687B2 (en)	1995-05-25
NZ244851A (en)	1997-07-27
GR3026526T3 (en)	1998-07-31
NO924103D0 (no)	1992-10-22
CA2081150A1 (fr)	1993-04-24
ZA928162B (en)	1993-05-05
NO924103L (no)	1993-04-26
CA2081150C (fr)	2001-04-10
EP0538754B1 (fr)	1998-01-14
AU2724492A (en)	1993-04-29
KR100252620B1 (ko)	2000-09-01
ATE162079T1 (de)	1998-01-15
US5951982A (en)	1999-09-14
HUT63063A (en)	1993-07-28
HU216020B (hu)	1999-04-28
ES2111031T3 (es)	1998-03-01
EP0538754A2 (fr)	1993-04-28
TW273514B (fr)	1996-04-01
IL103510A0 (en)	1993-03-15
DE4134982A1 (de)	1993-04-29
KR930007460A (ko)	1993-05-20
DE59209129D1 (de)	1998-02-19

Legal Events

Date	Code	Title	Description
2005-06-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO311965B1 (no)	2002-02-25	Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat
US8808667B2 (en)	2014-08-19	Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
JP2001502325A (ja)	2001-02-20	免疫調整の方法および組成物
HU230768B1 (hu)	2018-03-28	Aß peptidet kiválasztó humanizált ellenanyagok
WO2019095358A1 (fr)	2019-05-23	Protéine de fusion bifonctionnelle ciblant cd47 et pd-l1
CN109384845B (zh)	2022-06-21	一种cd40单克隆抗体、其制备方法及其应用
CA2468888C (fr)	2013-03-12	Recepteur-1 endothelial lymphatique et endothelial vasculaire commun (clever-1) et ses utilisations
CN110343180B (zh)	2021-03-30	抗ctla-4抗体及其应用
EP3556771A1 (fr)	2019-10-23	Anticorps de claudine 5 et médicament le contenant
CA2417874C (fr)	2012-10-02	Utilisation des inhibiteurs ox-2 pour le traitement du cancer
EP3858862A1 (fr)	2021-08-04	Anticorps anti pd-l1 et son utilisation
AU2018326106B2 (en)	2022-03-31	Composition For Preventing And Treating Skin Disease Comprising Material Specifically Binding To Vimentin-Derived Peptide
WO2024056098A1 (fr)	2024-03-21	Molécule d'adaptateur de cellule nkg2d-nkp46 et son utilisation
JP2002519303A (ja)	2002-07-02	脂質動員性を有する糖タンパク質およびその治療的適用
TW202305006A (zh)	2023-02-01	與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體
CN114790241A (zh)	2022-07-26	抗tigit抗体及其应用
RU2803148C2 (ru)	2023-09-07	Противоопухолевое средство и способ его оценки
HU217175B (hu)	1999-12-28	Új belhámvaszkuláris protein-1 (VAP-1), amely emberben a limfociták kötődését mediálja
CN116262791A (zh)	2023-06-16	钠钾atp酶的抗体及其应用